BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 21537035)

  • 1. Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    Nagle CM; Francis JE; Nelson AE; Zorbas H; Luxford K; de Fazio A; Fereday S; Bowtell DD; Green AC; Webb PM
    J Clin Oncol; 2011 Jun; 29(16):2253-8. PubMed ID: 21537035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
    Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
    Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer.
    Webb PM; Purdie DM; Grover S; Jordan S; Dick ML; Green AC
    Gynecol Oncol; 2004 Jan; 92(1):232-9. PubMed ID: 14751164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian cancer: can we make the clinical diagnosis earlier?
    Smith LH; Morris CR; Yasmeen S; Parikh-Patel A; Cress RD; Romano PS
    Cancer; 2005 Oct; 104(7):1398-407. PubMed ID: 16116591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The accurate staging of ovarian cancer using 3T magnetic resonance imaging--a realistic option.
    Booth SJ; Turnbull LW; Poole DR; Richmond I
    BJOG; 2008 Jun; 115(7):894-901. PubMed ID: 18485169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathways to the diagnosis of epithelial ovarian cancer in Australia.
    Jordan SJ; Francis JE; Nelson AE; Zorbas HM; Luxford KA; Webb PM; ;
    Med J Aust; 2010 Sep; 193(6):326-30. PubMed ID: 20854236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of survival in sex cord stromal tumors - an observational study with more than 25 years follow-up.
    Hölscher G; Anthuber C; Bastert G; Burges A; Mayr D; Oberlechner E; Schubert-Fritschle G; Sinz S; Sommer H; Schmalfeldt B; Engel J;
    Acta Obstet Gynecol Scand; 2009; 88(4):440-8. PubMed ID: 19191075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
    Wu M; Shen K; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).
    Wimberger P; Wehling M; Lehmann N; Kimmig R; Schmalfeldt B; Burges A; Harter P; Pfisterer J; du Bois A
    Ann Surg Oncol; 2010 Jun; 17(6):1642-8. PubMed ID: 20165986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cigarette smoking and survival after ovarian cancer diagnosis.
    Nagle CM; Bain CJ; Webb PM
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2557-60. PubMed ID: 17164386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership.
    Maringe C; Walters S; Butler J; Coleman MP; Hacker N; Hanna L; Mosgaard BJ; Nordin A; Rosen B; Engholm G; Gjerstorff ML; Hatcher J; Johannesen TB; McGahan CE; Meechan D; Middleton R; Tracey E; Turner D; Richards MA; Rachet B;
    Gynecol Oncol; 2012 Oct; 127(1):75-82. PubMed ID: 22750127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system.
    Stirling D; Evans DG; Pichert G; Shenton A; Kirk EN; Rimmer S; Steel CM; Lawson S; Busby-Earle RM; Walker J; Lalloo FI; Eccles DM; Lucassen AM; Porteous ME
    J Clin Oncol; 2005 Aug; 23(24):5588-96. PubMed ID: 16110018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer: the neglected diagnosis.
    Yawn BP; Barrette BA; Wollan PC
    Mayo Clin Proc; 2004 Oct; 79(10):1277-82. PubMed ID: 15473410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
    Panici PB; Maggioni A; Hacker N; Landoni F; Ackermann S; Campagnutta E; Tamussino K; Winter R; Pellegrino A; Greggi S; Angioli R; Manci N; Scambia G; Dell'Anna T; Fossati R; Floriani I; Rossi RS; Grassi R; Favalli G; Raspagliesi F; Giannarelli D; Martella L; Mangioni C
    J Natl Cancer Inst; 2005 Apr; 97(8):560-6. PubMed ID: 15840878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.